Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Canadian Retinal Trials Group.
Recruitment status was  Active, not recruiting
University of British Columbia
QLT Inc.
Vancouver Hospital
Information provided by:
Canadian Retinal Trials Group Identifier:
First received: September 6, 2005
Last updated: July 26, 2007
Last verified: July 2007
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Condition Intervention Phase
Age-Related Macular Degeneration
Drug: Triamcinolone Acetonide
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.

Resource links provided by NLM:

Further study details as provided by Canadian Retinal Trials Group:

Primary Outcome Measures:
  • Changes in visual acuity from baseline.

Secondary Outcome Measures:
  • Change in lesion characteristics from baseline.

Estimated Enrollment: 120
Study Start Date: January 2004
Estimated Study Completion Date: March 2008
Detailed Description:
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Individuals with predominantly classic, subfoveal CNV secondary to AMD.
  • No previous PDT Treatment in study eye.

Exclusion Criteria:

  • CNV from conditions, other than AMD.
  • Other disease that could be responsible for decreased vision.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00148551

Canada, British Columbia
Eye Care Centre
Vancouver, British Columbia, Canada
Sponsors and Collaborators
Canadian Retinal Trials Group
University of British Columbia
QLT Inc.
Vancouver Hospital
Study Director: David A Maberley, M.D. University of British Columbia
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00148551     History of Changes
Other Study ID Numbers: 01 (C03 - 0236) 
Study First Received: September 6, 2005
Last Updated: July 26, 2007
Health Authority: Canada: Health Canada

Keywords provided by Canadian Retinal Trials Group:
Macular Degeneration

Additional relevant MeSH terms:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Anti-Inflammatory Agents
Enzyme Inhibitors
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on May 25, 2016